FDA awards Synchrogenix contract extension for eCTD Management Software

By on Wednesday, July 19, 2017 in Industry Updates

On June 15th, the United States Food and Drug Administration (US FDA) awarded Synchrogenix a contract extension for the electronic common technical document (eCTD) submission management software:

GlobalSubmit REVIEW™ & GlobalSubmit VALIDATE™

This contract extension provides a continuity in the drug review process and marks the 12th anniversary of the exclusive relationship. Since June 2005, the FDA has solely utilized GlobalSubmit REVIEW™ & GlobalSubmit VALIDATE™ solutions as their eCTD platform.

Synchrogenix remains committed to being a transparent and trustworthy partner. We will continue to create best in class eCTD review and validation software and provide updates as we continue our partnership with the US FDA.

 

Post a Reply

Your email address will not be published. Required fields are marked *